Fig. 4From: Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis predictionPros and cons of blood-based biomarkers. CTCs, Circulating tumor cells; ctDNA, circulating tumor DNA; cfDNA, cell-free DNABack to article page